Menin inhibitors hold immense promise for addressing unmet needs in various pediatric leukemia subtypes, including infant KMT2A-r ALL, high-risk KMT2A-r AML, NUP98-r AML, and others. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.